Talaris Therapeutics, Inc.
NASDAQ:TALS
2.72 (USD) • At close October 19, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Assets: | ||||
| Current Assets: | ||||
| Cash & Cash Equivalents
| 13.67 | 18.614 | 17.589 | 38.978 |
| Short Term Investments
| 167.612 | 225.357 | 131.899 | 0 |
| Cash and Short Term Investments
| 181.282 | 243.971 | 149.488 | 38.978 |
| Net Receivables
| 0 | 0 | 0.374 | 0 |
| Inventory
| 0 | 0 | 0.813 | 0 |
| Other Current Assets
| 0.868 | 0.64 | 0.076 | 0.039 |
| Total Current Assets
| 185.613 | 246.514 | 150.751 | 40.794 |
| Non-Current Assets: | ||||
| Property, Plant & Equipment, Net
| 7.991 | 4.804 | 2.013 | 1.127 |
| Goodwill
| 0 | 0 | 0 | 0 |
| Intangible Assets
| 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0.111 | 0.104 | 0.014 | 0.02 |
| Total Non-Current Assets
| 8.102 | 4.908 | 2.027 | 1.147 |
| Total Assets
| 193.715 | 251.422 | 152.778 | 41.942 |
| Liabilities & Equity: | ||||
| Current Liabilities: | ||||
| Account Payables
| 3.887 | 2.556 | 0.767 | 0.667 |
| Short Term Debt
| 0.91 | 0 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0.156 | 0.032 |
| Deferred Revenue
| 0 | 0 | 0 | 0 |
| Other Current Liabilities
| 6.665 | 5.431 | 2.637 | 1.624 |
| Total Current Liabilities
| 11.462 | 7.987 | 3.404 | 2.291 |
| Non-Current Liabilities: | ||||
| Long Term Debt
| 1.974 | 0 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 0.224 | 0.626 | 1.369 | 56.753 |
| Total Non-Current Liabilities
| 2.198 | 0.626 | 1.369 | 56.753 |
| Total Liabilities
| 13.66 | 8.613 | 4.773 | 59.044 |
| Equity: | ||||
| Preferred Stock
| 0 | 251.422 | 0 | 0 |
| Common Stock
| 0.004 | 0.004 | 0.003 | 0.001 |
| Retained Earnings
| -164.741 | -90.847 | -43.014 | -20.307 |
| Accumulated Other Comprehensive Income/Loss
| -0.721 | -0.078 | -0.013 | 0 |
| Other Total Stockholders Equity
| 345.513 | 82.308 | 191.029 | 3.204 |
| Total Shareholders Equity
| 180.055 | 242.809 | 148.005 | -17.102 |
| Total Equity
| 180.055 | 242.809 | 148.005 | -17.102 |
| Total Liabilities & Shareholders Equity
| 193.715 | 251.422 | 152.778 | 41.942 |